The gross proceeds, before deducting underwriting discounts and offering expenses, from the sale of the aggregate 12.34 million shares were approximately $50 million and the net proceeds, after deducting underwriting discounts and offering expenses, were approximately $47.7 million.
Pacific Growth Equities, Broadpoint Capital, and Fortis Securities acted as underwriters for this offering. Anesiva is a biopharmaceutical company focused on the development and commercialization of novel therapeutic treatments for pain management.